We recently published an article titled Trade Tensions Weigh Heavily on 10 Stocks. In this article, we are going to take a ...

Fintel reports that on March 6, 2025, HC Wainwright & Co. initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: Azul (AZUL) 69.46% +4.74, Direxion Daily ...

ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...

Private Advisor Group LLC trimmed its position in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 75.4% during the 4th ...

Highlights,The New York State Common Retirement Fund raised its stake in ImmunityBio by 62.8% in the fourth quarter.,Several ...

Fintel reports that on March 6, 2025, HC Wainwright & Co. initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy recommendation. As of March 4, 2025, the average one-year price target for ...

In this article, we are going to take a look at where ImmunityBio Inc. (NASDAQ:IBRX) stands against the other stocks. The stock market kicked off the trading week in a bloodbath, erasing last week ...

ImmunityBio ( NASDAQ:IBRX ) Full Year 2024 Results Key Financial Results Revenue: US$14.7m (up by US$14.1m from FY... CULVER CITY, Calif., March 03, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a ...

ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) traded up 6.8% on Tuesday following a better than expected earnings announcement. The stock traded as high as $3.01 and last traded at $3.05.

ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.19 per share a year ago. These figures are ...